1. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy

   • George Lau
   • Ming-Lung Yu
   • Masao Omata

   Guidelines 24 August 2021 Pages: 1031 - 1048

   

2. Connection between HPS and ACLF: a solution of chaos?

   • Hitoshi Maruyama
   • Shuichiro Shiina

   Editorial 04 October 2021 Pages: 1049 - 1052

   

3. Effect of microbiota metabolites on the progression of chronic hepatitis B virus infection

   • Xiu Sun
   • Calvin Q. Pan
   • Huichun Xing

   Review Article 01 October 2021 Pages: 1053 - 1067

   

4. The global trends and regional differences in incidence and mortality of hepatitis A from 1990 to 2019 and implications for its prevention

   • Guiying Cao
   • Wenzhan Jing
   • Min Liu

   Original Article Open access 03 August 2021 Pages: 1068 - 1082

   

5. Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B

   • Hye Won Lee
   • Young Youn Cho
   • Soo Young Park

   Original Article 16 August 2021 Pages: 1083 - 1092

   

6. Diabetes is associated with poor short-term prognosis in patients with hepatitis B virus-related acute-on-chronic liver failure

   • Han Hu
   • Xinxin Hu
   • Shide Lin

   Original Article 10 August 2021 Pages: 1093 - 1102

   

7. Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load

   • Baijun Li
   • Zhaozhe Liu
   • Yan Wang

   Original Article 26 July 2021 Pages: 1103 - 1108

8. Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)

   • Ming-Lun Yeh
   • Chao-Hung Hung
   • Ming-Lung Yu

   Original Article 07 August 2021 Pages: 1109 - 1121

   

9. Hepatic stellate cells-specific LOXL1 deficiency abrogates hepatic inflammation, fibrosis, and corrects lipid metabolic abnormalities in non-obese NASH mice

   • Aiting Yang
   • Xuzhen Yan
   • Hong You

   Original Article 20 May 2021 Pages: 1122 - 1135

   

10. First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients

    • Jee-Fu Huang
    • Chia-Yen Dai
    • Wan-Long Chuang

    Original Article 12 August 2021 Pages: 1136 - 1147

    

11. Histological severity of nonalcoholic fatty liver disease is associated with 10-year risk for atherosclerotic cardiovascular disease

    • Ji Hye Park
    • Bo Kyung Koo
    • On behalf of the Innovative Target Exploration of NAFLD (ITEN) Consortium

    Original Article 03 June 2021 Pages: 1148 - 1159

    

12. The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes

    • Lukas Hartl
    • Mathias Jachs
    • Thomas Reiberger

    Original Article Open access 21 May 2021 Pages: 1160 - 1173

    

13. Increased risk of cancer in patients with primary sclerosing cholangitis

    • Aiva Lundberg Båve
    • Annika Bergquist
    • Caroline Nordenvall

    Original Article Open access 06 August 2021 Pages: 1174 - 1182

    

14. Portal vein thrombosis associated with high 14-day and 6-week rebleeding in patients after oesophageal variceal band ligation: a retrospective, multicentre, nested case–control study

    • Zhanjuan Gao
    • Jingrun Zhao
    • Yanjing Gao

    Original Article 22 July 2021 Pages: 1183 - 1195

    

15. A network meta-analysis of direct oral anticoagulants for portal vein thrombosis in cirrhosis

    • Cheng Han Ng
    • Darren Jun Hao Tan
    • Mark D. Muthiah

    Original Article 21 August 2021 Pages: 1196 - 1206

    

16. Hepatopulmonary syndrome is related to the development of acute-on-chronic liver failure and poor prognosis in cirrhotic patients

    • Seul Ki Han
    • Moon Young Kim
    • Soon Koo Baik

    Original Article 28 July 2021 Pages: 1207 - 1214

    

17. Survival analysis between laparoscopic and open hepatectomy for hepatocellular carcinoma: a meta-analysis based on reconstructed time-to-event data

    • Qiang Sun
    • Xiangda Zhang
    • Yajin Chen

    Original Article 13 July 2021 Pages: 1215 - 1235

    

18. Targeted inhibition of FGF19/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma

    • David Wai Meng Tai
    • Thi Bich Uyen Le
    • Hung Huynh

    Original Article 31 July 2021 Pages: 1236 - 1246

    

19. Iodized oil computed tomography versus ultrasound-guided radiofrequency ablation for early hepatocellular carcinoma

    • Chih-Horng Wu
    • Po-Chin Liang
    • Jia-Horng Kao

    Original Article 02 August 2021 Pages: 1247 - 1257

    

20. Volumetric assessment and clinical predictors of cirrhosis in patients undergoing hepatectomy for hepatocellular carcinoma with presumed normal liver function

    • Takayuki Shimizu
    • Taku Aoki
    • Keiichi Kubota

    Original Article 23 August 2021 Pages: 1258 - 1267

    

21. Efficacy of apatinib in patients with sorafenib–transarterial chemoembolization refractory hepatocellular carcinoma: a retrospective study

    • Yanyan Cao
    • Tao Ouyang
    • Chuansheng Zheng

    Original Article 20 August 2021 Pages: 1268 - 1277

    

22. Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies

    • Takanori Ito
    • Masatoshi Ishigami
    • Mitsuhiro Fujishiro

    Original Article 09 August 2021 Pages: 1278 - 1287